1 1

Lean Strength Bundle

Lean Strength Bundle

$576.00
$640.00 $576.00
Sale Sold out
Shipping calculated at checkout.

The Lean Strength Bundle (LSB) is a dual-component research set designed to investigate anabolic and growth-related pathways, combining: 

  • 3X Blend (Tesamorelin, MGF, Ipamorelin): 

    • Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered to enhance growth hormone pulsatility in experimental settings. 

    • Mechano-Growth Factor (MGF/IGF‑1Ec) is a splice variant of IGF‑1 that activates localized IGF‑1 receptor signaling, supporting muscle cell proliferation and tissue repair in laboratory studies. 

    • Ipamorelin is a selective ghrelin receptor (GHSR) agonist known for its ability to stimulate growth hormone release without significant impact on other pituitary hormones [1][2][3]. 

  • IGF‑1 LR3: A long-acting IGF‑1 analogue with a 13-amino-acid N-terminal extension and Arg³ substitution. IGF‑1 LR3 exhibits improved receptor binding, reduced affinity for binding proteins, and a significantly extended half-life (~20–30 hours) compared to native IGF‑1. It is widely studied for its role in cell growth and anabolic signaling [4][5]. 

Together, these components allow preclinical research into synergistic effects on protein synthesis, cellular regeneration, and growth factor signaling pathways. 

This bundle is intended for laboratory research purposes only.

 

Citations

  1. Stanley TL, et al. “Effects of tesamorelin, a growth hormone-releasing factor analogue, in preclinical models.” J Clin Endocrinol Metab. 2010;95(9):4353–4360. PMID: 20554711. 
  2. Min S‑Y, et al. “Mechano-growth factor (MGF/IGF‑1Ec) induces muscle stem cell activation and proliferation in vitro.” FASEB J. 2009;23(1):294–305. PMID: 18806136.
  3. Sanchez J, et al. “Ipamorelin selectively stimulates GH release without affecting other pituitary hormones in animal studies.” J Endocrinol. 2007;195(3):507–514. PMID: 17673578.
  4. PubChem Compound Summary – IGF‑1 LR3 (CID 18357622): modified IGF‑1 with Arg³ substitution and N-terminal extension for increased activity and stability.
  5. Jones JI, Clemmons DR. “Insulin-like growth factors and their binding proteins: biological actions and molecular mechanisms.” Endocrine Reviews. 1995;16(1):3–34. PMID: 7564154. 
View full details

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.